Children born with defects that impair the heart's lower chambers undergo a series of invasive surgeries early in life. The first surgery includes implantation of a plastic tube called a shunt to improve blood flow. However, as children grow, the shunt is often replaced to accommodate their changing bodies. Now, researchers have designed a shunt that expands when activated by light. If developed successfully, this device could reduce the number of open-chest surgeries these children receive.
The researchers will present their results at the fall meeting of the American Chemical Society (ACS). ACS Fall 2024 is a hybrid meeting being held virtually and in person Aug. 18-22; it features about 10,000 presentations on a range of science topics.
"After the surgeon first puts in the tube, these children often have to go through an additional two or three, maybe even four, surgeries just to implant a slightly larger tube," says Christopher Rodell, who is presenting the research. "Our goal is to expand the inside of the tube with a light-emitting catheter that we insert inside the shunt, completely eliminating the need for additional surgeries." Rodell is an assistant professor of biomedical engineering at Drexel University.
These congenital heart defects affect the organ's lower chambers, known as ventricles, resulting in restricted blood flow to the lungs and other parts of the body. Without surgery, babies with these disorders cannot survive. Often born undersized, these infants can grow rapidly after their first shunt implantation surgery. To accommodate their growth, surgeons often perform yet another open-chest surgery. Each time this procedure is performed, it creates a risk to the child. In a study of 360 patients who underwent the initial heart reconstruction procedure, 41 needed additional surgeries to implant a larger shunt and seven died as a result.
Previously, Rodell's colleagues at Drexel, Amy Throckmorton and Kara Spiller, built an expandable prototype to potentially replace the most commonly used type of shunt. They did so by coating the interior of the tube with a hydrogel that contains a network of water-surrounded polymers attached to each other by bonds called crosslinks. The formation of new crosslinks forces water out of the hydrogel and pulls the polymers together, contracting the hydrogel and widening the inside of the shunt. In the initial design, the new crosslinks formed automatically, without an external trigger.
Rodell joined Throckmorton and Spiller to help them reengineer the shunt so the materials would be safe for clinical use and so it could be adjusted to meet the needs of individual children. He accomplished this by developing new polymers for a hydrogel that would form new crosslinks and increase the shunt's inner diameter in response to a trigger. To initiate crosslinking on demand, Rodell decided to use blue light because this wavelength carries enough energy to initiate the reaction but is safe for living tissue.
Light has always been one of my favorite triggers, because you can control when and where you apply it."
Christopher Rodell, assistant professor of biomedical engineering, Drexel University
For the new device, Rodell and his team led by graduate student Akari Seiner are using a fiber-optic catheter, essentially a long, thin tube with a light-emitting tip. To activate the light-sensitive hydrogel inside the shunt, they intend for surgeons to insert the catheter into an artery near the armpit then maneuver it into position, eliminating the need to open the baby's chest.
In lab experiments, they found they could expand the shunt incrementally, with the amount of expansion varying according to the length of light exposure -; results indicating that once implanted, adjustments to the shunt could be customized to each child. They found they could dilate the shunt by as much as 40%, expanding its diameter from 3.5 millimeters to 5 millimeters -; nearly the size of the largest shunt implanted in children. They also assessed how blood cells and blood vessels might respond to the modified shunt. They found no evidence that the implanted tube caused the formation of blood clots, an inflammatory response or other reactions that could pose potential health problems.
Next, the team plans to test full-length shunt prototypes in an artificial set-up mimicking the human circulatory system. If these experiments are successful, the researchers intend to move on to experiments in animal models. This technology could be useful beyond single-ventricle heart disorders, according to Rodell. Surgeons could, for example, use similar tubes to replace blood vessels in children injured in a car accident.
"In these procedures, you run into the same problem: Children aren't just tiny adults; they continue to grow," Rodell says. "That's something we need to account for in biomaterials, how that graft will behave over time."
The research was funded by The Hartwell Foundation.
New nasal spray form of bumetanide shows promise for heart failure treatment